• PDF / 176,186 Bytes
• 15 Pages / 504.57 x 720 pts Page_size
• 31 Downloads / 199 Views

DOWNLOAD

REPORT

REVIEW ARTICLE

© 2005 Adis Data Information BV. All rights reserved.

Ocular Pharmacokinetics and Safety of Ciclosporin, a Novel Topical Treatment for Dry Eye Diane D.-S. Tang-Liu and Andrew Acheampong Allergan Inc., Irvine, California, USA

Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247 1. Physicochemical Properties and Ophthalmic Dosage Forms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248 2. Bioanalytical Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 3. Pharmacokinetics of Ophthalmic Ciclosporin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251 3.1 Ocular Absorption and Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251 3.1.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251 3.1.2 Humans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252 3.2 Ocular Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252 3.3 Ocular and Systemic Cyclosporin Concentrations in Humans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253 4. Ocular Safety of Ciclosporin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253 4.1 In Vitro Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253 4.2 Animal Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254 4.2.1 Topical Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254 4.2.2 Systemic Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254 4.3 Oral Administration in Humans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254 5. Systemic Drug Exposure and Safety after Topical Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 5.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 5.2 Humans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 5.3 Implications for Adverse Effects . . . . .

Recommend Documents

Topical Steroids in Management of Dry Eye Disease

151 3 240KB

Post-blepharoplasty Dry Eye

165 94 17MB

Ocular Pharmacokinetics and Drug Delivery Challenges

166 8 419KB

Is gabapentin effective in dry eye disease and neuropathic ocular pain?

156 76 358KB

Dry Eye Syndrome: Severe Ocular Surface Inflammatory Syndrome Post LASIK Caused by Blepharitis

141 0 208KB

iRGD decorated liposomes: A novel actively penetrating topical ocular drug delivery strategy

144 64 2MB

Treatment of Ocular Rosacea

154 21 5MB

Dry eye in the COVID-19 era: how the measures for controlling pandemic might harm ocular surface

146 37 292KB

Clinical Efficacy and Safety Profile of Topical Etofenamate in the Treatment of Patients with Musculoskeletal Disorders:

203 76 408KB

Clinical characteristics of dry eye with ocular neuropathic pain features: comparison according to the types of sensitiz

143 64 518KB

Tear proteomic profile in three distinct ocular surface diseases: keratoconus, pterygium, and dry eye related to graft-v

121 89 3MB

First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloprote

180 67 1MB